iShares Global Tech ETF vs Smith & Nephew plc — how do they compare? iShares Global Tech ETF trades at $137.1, while Smith & Nephew plc trades at $30.19 (market cap $12.64B). The key difference: Smith & Nephew plc pays a 2.57% dividend while iShares Global Tech ETF pays none, and iShares Global Tech ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| IXN | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $149.74 | $38.70 |
52-Week Low | $94.04 | $28.73 |
Market Cap | — | $12.64B |
Enterprise Value | — | $15.41B |
Dividend Yield | — | 2.57% |
Signals from Pluang's Aura AI — not financial advice
IXN trades at $132.95 with minimal daily movement (+0.25%). Technical indicators show a neutral to bearish bias with mixed signals from moving averages and oscillators. The stock faces resistance near $139-$141 while finding support around $133-$136. Recent analysis highlights strong technology sector exposure but cautions about elevated valuations and concentration risks in the portfolio.
The outlook remains cautious as current price levels reflect significant optimism about AI-driven growth. Investment opportunity lies in continued technology sector leadership, while risks include valuation concerns and sector concentration. Analyst sentiment leans neutral with expectations for clearer earnings growth catalysts before more bullish positioning.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Trailing returns across standard periods
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →